IL1B and type 2 diabetes mellitus: The results from the CANTOS study served as a proof of concept for the ability of canakinumab to reduce cardiovascular mortality by virtue of its marked anti-inflammatory properties, making IL-1β antagonism an attractive therapeutic approach to reduce cardiovascular risk and potentially improve glucose homeostasis in patients with and without T2D.